MedTrace Logo

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

NCT07399678 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-05-22

No results posted yet for this study

Summary

A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes

Conditions

  • Overweight or Obese Adults
  • Overweight or Obese, Type 2 Diabetes

Interventions

DRUG

ALV-100

Participants will receive multiple ascending doses of ALV-100.

DRUG

Placebo

Participants will receive placebo matching ALV-100, volume-matched to active dose.

Sponsors & Collaborators

  • Alveus Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Karen Tornøe, MD, PhD · Alveus Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-29
Primary Completion
2027-04-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07399678 on ClinicalTrials.gov